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Abstract 29 
Molecular determinants underlying interferon (IFN)-macrophage biology can help delineate 30 
enzyme systems, pathways and mechanisms for enabling host-directed therapeutic approaches 31 
against infection. Notably, while the IFN antiviral response is known to be directly coupled to 32 
mevalonate-sterol biosynthesis pathway mechanistic insight for providing host pathway-33 
therapeutic targets, remain incomplete.  Here, we show that Nampt and Sirt6 are coordinately 34 
regulated upon immune activation of macrophages and contribute to the IFN-sterol antiviral 35 
response. In silico analysis of the Nampt and Sirt6 promoter regions identified multiple core 36 
immune gene-regulatory transcription factor sites, including Stat1, implicating a molecular link 37 
to IFN control. Experimentally, we show using a range of genetically IFN-defective 38 
macrophages that the expression of Nampt is stringently regulated by the Jak/Stat-pathway 39 
while Sirt6 activation is temporally displaced in a partial IFN-dependent manner. We further 40 
show that pharmacological inhibition of Nampt and small interfering RNA (siRNA)-mediated 41 
inhibition of Nampt and Sirt6 promotes viral growth of cytomegalovirus in both fibroblasts and 42 
macrophages. Our results support the notion of pharmacologically exploiting immune regulated 43 
enzyme systems of macrophages for use as an adjuvant-based therapy for augmenting host 44 
protective pathway responses to infection.  45 
 46 
 47 
 2 
Introduction 48 
Infection is a dynamically complex and multifaceted process requiring not only the avoidance 49 
of immune countermeasures but also the exploitation of host cellular networks and machinery 50 
by the pathogen. In many cases, parastization by pathogens and especially by viruses requires 51 
remodeling of metabolic and energy resources for the successful production of progeny. 52 
Notably, the immune system has been found to cross regulate these resources and processes as 53 
an evolutionary selected countermeasure. For example, IFN induced consumption of 54 
tryptophan, by the Indoleamine 2,3 Dioxygenese (IDO) pathway, has been shown to inhibit 55 
replication of several intracellular organism including hCMV (1-5). More recently interferon 56 
regulation of the sterol biosynthesis pathway has been shown to be a central biosynthetic 57 
pathway targeted by the immune system for broad host-protection against infection.  58 
 59 
In this scenario, Toll-like receptor activation of macrophages by pathogens leads to the 60 
production of type I interferons which coordinately regulate a marked and sustained reduction 61 
in the mevalonate-sterol biosynthetic pathway, and whereby a wide-spectrum of different 62 
human and animal viruses have been shown to be sensitive to suppression of the pathway (6-63 
20). The currently known molecular pathways for down-regulating the sterol pathway involve 64 
the IFN induction of an hydroxylase enzyme (Ch25h) and its cognate regulatory metabolite, 65 
25-hydroxycholesterol (25HC) that potently inhibits, at the protein level, the master 66 
transcription factor for sterol biosynthesis (SREBP2) (8, 21), and also the key regulated 67 
mevalonate reductase, HMGCR (22), and additionally IFN regulated microRNAs (miR342-5p), 68 
that coordinate changes in the enzymatic flux of the cholesterol pathway within the cell (6). 69 
However, there remains yet to be identified transcriptional or epigenetic mechanisms for 70 
suppression of SREBP2 and sterol biosynthesis.  71 
 72 
More broadly, there is increasing evidence showing connections between immune signaling, 73 
such as interferon (IFN) signaling, and the regulation of sterol, sugar, and fatty acid metabolism 74 
(23-26). While the cell typically induces changes through rapid established routes such as the 75 
PI3K/AKT/mTOR signaling pathway, these changes are not sustained over a longer period time 76 
and do not support the increased needs for de novo lipogenesis. In the context of cellular stress 77 
and inflammation, Sirtuins (SIRTs) are known to play sustained roles in protecting against 78 
cellular stress through epigenetic control of metabolic pathways (27, 28). This includes the 79 
regulation of glycolytic and lipid metabolism by the nicotineamide adenine dinucleotide 80 
(NAD+)-dependent deacetylases SIRT1 and SIRT6 (29-32). Metabolic coupling is strictly 81 
dependent on NAD+ production through de novo biosynthesis from tryptophan or through the 82 
nicotineamide (NAM) salvage pathway, which is regulated by the rate-limiting enzyme 83 
nicotineamide phosphatidyltransferase (NAMPT). It is notable that NAD+-dependent activation 84 
of SIRT6 has been shown to repress the SREBF2 promoter (31), and thereby directly linking 85 
SIRT6 activity to sterol metabolism. However, whether NAMPT or SIRT6 are coordinately 86 
regulated by the IFN macrophage antiviral response is not known. Most notably this remains a 87 
central unanswered question to the notion of using macrophage interferon biology as a guiderail 88 
for identifying host-directed druggable targets as anti-infectives.  89 
In the present report, we find that Nampt and Sirt6 are coordinately regulated upon 90 
immune activation of macrophages and contribute to the interferon antiviral response. The 91 
coupling to the IFN response is via direct transcriptional activation of NAMPT through the 92 
JAK/STAT signaling pathway. We show that pharmacological inhibition of Nampt and small 93 
interfering RNA (siRNA)-mediated inhibition of Nampt and Sirt6 enhances the viral growth of 94 
cytomegalovirus (mCMV) in both fibroblasts and macrophages. These findings support the 95 
proposition that immune regulated enzyme systems may be used as an adjuvant therapy for 96 
augmenting the host protective response to infection. 97 
 3 
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 99 
Results  100 
Co-ordinate regulation of Nampt and Sirt6 are part of the interferon-metabolic anti-101 
viral response. 102 
We first investgated whether murine Nampt and Sirt6 and human NAMPT and SIRT6 promoter 103 
regions contained any putative transcriptional binding sites (TFBS) for immune-regulatory 104 
transcription factors (Figure 1, Supplementary tables 1-4). By using the sequence analysis tool 105 
PROMO (33, 34), and manual procurement by comparing putative binding sites to published 106 
consensus binding sequences, an array of significant binding sites (restricted to 15% 107 
dissimilarity) for core immune-activated transcription factors, including AP-1, NFB (defined 108 
here as DNA binding activity constituted either by p50 homodimer, a p50/p65 heterodimer, or 109 
a heterotetramer), RELA (p65 subunit of NFB), GATA1 and GATA2, were identified within 110 
(-1kb upstream of) the murine Nampt and Sirt6 promoter regions (Figure 1). PROMO analysis 111 
of the human NAMPT and SIRT6 promoter regions identified similar binding sites, suggesting 112 
that the overall activation mode of these genes is conserved between humans and mice. Notably, 113 
several putative Signal Transducers and Activators of Transcription 1 (STAT1) sites were 114 
identified across the Nampt promoter region, suggesting Nampt expression might be driven 115 
directly by the activation of the JAK/STAT signaling pathway (Figure 1). A putative Oct cluster 116 
(OCT1/2/(3/4)) was also identified in the distal Nampt promoter region, in close proximity to 117 
putative NFB, RELA, and STAT1 binding sites. While the promoter region of Sirt6 did not 118 
contain any putative STAT1 binding sites, it was dominated by putative binding sites for 119 
Activator protein 1 (AP-1), c-JUN, c-FOS, and NFB. The AP-1 structure is a heterodimer 120 
composed of proteins belonging to the c-FOS, c-JUN, Activating transcription factor (ATF), 121 
and Jun dimerization protein (JDP) families (35, 36). Consistent with its reported activity, the 122 
putative AP-1 binding sites were found in close proximity to either c-FOS, c-JUN, or in areas 123 
containing cis-located c-FOS and c-JUN binding sites (Figure 1). AP-1, an early response 124 
transcription factor, has been reported to regulate gene expression in response to various 125 
stimuli, including cytokine stimulation and bacterial and viral infections (37).  126 
The presence of several putative immune-gene regulatory transcription factor binding sites, 127 
prompted us to investigate whether Nampt and Sirt6 expression was induced by infection 128 
(Figure 2). The relative expression of Nampt and Sirt6 in mCMV-infected NIH-3T3 and p53 129 
mouse embryonic fibroblasts (p53-MEFs) was measured using Quantitative reverse-130 
transcriptase Polymerase Chain Reaction (qRT-PCR) (Figure 2A-B). mCMV infection of NIH-131 
3T3 and p53-MEFs resulted in significantly higher levels of Nampt expression during the first 132 
6 hours of infection (Figure 2A-B). While an early increased Sirt6 expression was not observed, 133 
a significantly higher expression was observed in NIH-3T3 after 10 hours of infection, 134 
indicating a delayed response. Similarly, the temporal expression profiles (over 24 hours) of 135 
Nampt and Sirt6 were investigated in mCMV infected bone marrow derived macrophages 136 
(BMDM).  Following mCMV infection, cells were harvested every 2 hours until 10 hours post 137 
treatment (0 (0 hours after viral adsorption or poly(I:C) treatment), 2, 4, 6, 8, 10 hours) and at 138 
24 hours, followed by transcriptomic profiling and modeling of their temporal expression. In 139 
these experiments, polynomial fitting of the smoothened data was used to determine whether 140 
the expression profiles of Nampt and Sirt6 changed significantly (where a R2 > 0.9 indicated 141 
significant change) with time in infected BMDM. (Supplementary tables 5-6). In addition 142 
further statistical evaluation was performed by determining the p-value of the fitted model in 143 
relation to a horizontal flat line, where a significant p value predicted a temporal change and a 144 
non-significant p value is predicted of non fluctuation in expression. Consistent with the 145 
observations in NIH-3T3s and p53-MEFs, mCMV infection of BMDM resulted in a significant 146 
early and dynamic expression of Nampt (Figure 2C and Supplementary table 5), with a peak at 147 
 4 
5 hours, followed by a steady decline. Moreover, similarly to the observations in NIH-3T3s and 148 
p53-MEFs, temporal expression analysis revealed that mCMV infected BMDM exhibited a 149 
delayed but continuous, albeit lower than Nampt, significant Sirt6 expression (Figure 2C and 150 
Supplementary table 6). Collectively, these results show that while Nampt and Sirt6 are both 151 
induced in response to mCMV infection, their response time differs from each other irrespective 152 
of cell type, indicative of potential differential transcriptional regulation. 153 
 154 
Nampt gene expression is activated by the Jak/Stat signaling pathway and induced by 155 
both type-I and type-II IFNs, while respone of Sirt6 is indirect or restricted to type-I IFN 156 
response. 157 
The presence of the several putative STAT1 binding sites in the Nampt promoter region 158 
suggests that Nampt expression is induced in a JAK/STAT signaling pathway-dependent 159 
manner. To initially investigate this, the synthesis of Nampt mRNA was measured Tyk-2-160 
deficient BMDM (Figure 3). Nampt mRNA synthesis was investigated in mCMV infected wild-161 
type and Tyk2-deficient BMDM at 1-1.5 hours post infection and at 6-6.5 hours post infection 162 
(Figure 3A). The non-receptor tyrosine-protein kinase Tyk2 has been implicated in type-I IFN, 163 
IL-6, IL-10, and IL-12 signaling (38-42). Consistent with the identification of putative STAT1 164 
binding sites, mCMV infection of Tyk2-deficient (Tyk2-/-) BMDM resulted in a much-reduced 165 
Nampt synthesis, compared to infected wild-type cells, suggesting that Nampt is, at least partly, 166 
induced in a JAK/STAT pathway-dependent manner (Figure 3A).  167 
 The presence of putative STAT1 binding sites and the observed dependence of 168 
Nampt expression on TYK2 and on the JAK/STAT signaling pathway poses the question 169 
Whether the induced expression of Nampt and Sirt6 is dependent on type I IFN signaling? To 170 
investigate this, the expression of Nampt and Sirt6 was assessed in polyinosinic:polycytidylic 171 
acid (poly(I:C)) treated Ifnb-deficient BMDM and compared to the response in mCMV infected 172 
Ifnb1-deficient (C57BL/6J Ifnb1-/-) BMDM (Figure 3B-C). Poly(I:C), a ligand of Toll like 173 
receptor 3 (TLR3), is structurally similar to double-stranded RNA and is, thus, used to simulate 174 
viral infections. Following mCMV infection or poly(I:C) treatment, cells were, as decribed 175 
above (Figure 2), harvested every 2 hours until 10 hours post treatment and at 24 hours, 176 
followed by transcriptomic profiling and modeling of their temporal expression. As in Figure 177 
2C, mCMV infection of wild-type BMDM resulted in an early dynamic expression of Nampt. 178 
Similar to Nampt, mCMV infection of wild-type BMDM significantly induced, albeit at a lower 179 
level, the expression of Sirt6 expression peaking downstream of Nampt. Poly(I:C) treatment of 180 
wild-type BMDM, resulted in a significant temporal activation of both Nampt and Sirt6, 181 
indicating that the observed expression is a host-driven response to infection (Figure 3C, 182 
Supplementary tables 7-8). The level of Nampt activation following mCMV infection was 183 
significantly reduced in Ifnb1-deficient cells, suggesting that a robust Nampt expression 184 
response is IFN-dependent (Figure 3B). While the robustness in Nampt expression was lost, a 185 
small significant temporal change in the expression profile was observed, suggesting that 186 
Nampt expression is possibly governed by other factors or pathways including by other type I 187 
Ifns but that the magnitude of expression is strongly dependent on intact IFN-signaling. The 188 
early expression of Sirt6 was, however, not extensively altered in mCMV infected or poly(I:C) 189 
treated Ifnb-deficient cells. The expression was similar to wild-type cells up until 7 hours post 190 
infection and up until 5 hours post poly(I:C) treatment. This was followed by a reduction in 191 
expression,  indicating that early but not late activation of Sirt6 expression following mCMV 192 
infection and poly(I:C) treatment is induced independently of IFN (Figure 3B-C and 193 
Supplementary tables 6 and 8). Together, these results indicate that Nampt and Sirt6 are coupled 194 
to the type I IFN response in macrophages.  195 
 196 
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Further in our BMDM, where stimulation with physiologically relevant 197 
concentration of IFN has been previously determined (47), IFN induced the expression of 198 
Nampt, peaking at 6 hours post treatment (Supplementary figure 1 and Supplementary table 9). 199 
Moreover, to further investigate the dependence of Nampt and Sirt6 expression on the type-II 200 
IFN response, the level of newly transcribed Nampt and Sirt6 mRNA was measured every 30 201 
minutes, over a period of 8 hours, using reverse transcriptase-quantitative PCR (qRT-PCR) in 202 
BMDM stimulated with IFN (Figure 3D). Stimulation with IFN resulted, after 2 hours of 203 
infection, in an eight-times increase in de novo transcribed Nampt RNA levels, followed by a 204 
rapid drop in Nampt mRNA. Sirt6 mRNA levels were on the other hand not affected by IFN 205 
stimulation, further suggesting that it is not a type-II IFN stimulated gene. Notably, the increase 206 
in Nampt mRNA expression was followed by a drop in Srebf2 expression, consistent with 207 
previously published data from Blanc et al. (7).  208 
The dependence on type-II IFN and JAK/STAT signaling was further investigated 209 
in wild-type and Stat1-deficient (Stat1-/-) p53-MEFs stimulated with IFN (Figure 3E-F). 210 
Steady state levels of Nampt mRNA was investigated at 1, 2, 4, 8, and 16 hours post treatment 211 
and compared to untreated (0h) cells (Figure 3E). IFN activated of wild-type cells resulted, as 212 
early as 2 hours post treatment, in a significantly increased expression of Nampt compared to 213 
untreated cells (statistical significance depicted with #), suggesting that Nampt is a type-I IFN 214 
responsive gene. In the IFN activated Stat1-deficient (Stat1-/-) cells, a significantly increased 215 
Nampt expression, compared to the untreated Stat1-deficient control (not shown), was only 216 
observed at later time points (16 hours). This expression was significantly reduced at all time 217 
points compared to activated wild-type cells, indicating that Nampt is dependent on intact Stat1 218 
signaling, consistent with the identification of putative STAT1 binding sites within the Nampt 219 
promoter region. 220 
Moreover, loss of Stat1 resulted in a significantly reduced expression of Sirt6 221 
compared to the wild-type p53-MEFs (Figure 3F). Notably, unlike Nampt, Sirt6 mRNA 222 
expression in wild-type cells did not increase statistically with time (compared to untreated 223 
control), suggesting that it is not a type-II IFN stimulated gene. Nor did the expression change 224 
significantly in Stat1-deficient cells to the respective untreated control. It is possible to 225 
speculate that Stat1 signaling is required for the basal, but not induced, Sirt6 expression. The 226 
absence of identified STAT1 binding sites in combination with the absence of gene induction 227 
with time further support the notion that this activation is indirect. Collectively, these results 228 
show that Nampt and Sirt6 are both induced in response to mCMV infection and suggest that 229 
Nampt is an interferon-stimulated gene (ISG), with Nampt expression being an immediate-230 
response gene induced by type-I and type-II IFN in a JAK/STAT dependent manner.  231 
 232 
Intact type-I IFN signaling is required for strong infection-induced expression of 233 
upstream, but not downstream, TLR signaling pathway components.  234 
Infection with double-stranded DNA viruses, such as CMV, are known to trigger the common 235 
TLR signaling pathway that elicits the activation of NFB and MAPK through the Myd88 236 
adaptor (43), while other pathways, such as the IPS-1 and STING mediated pathways, induce 237 
type-I IFN synthesis (44-46) resulting in downstream target activation, e.g. Nampt and Sirt6. 238 
To explore the gene activation of factors belonging to these pathways, the temporal gene 239 
expression profiles of Myd88, p50 (Nfb1), p65 (Rela), Trif (Ticam1), Rig-I (Ddx58), Mda5 240 
(Ifih1), Ips-1 (Mavs), Sting (Tmem173), and cGas (Md21d1) were investigated in mCMV 241 
infected or poly(I:C) treated wild-type and Ifnb1-deficient BMDM (Figure 4 and 242 
Supplementary tables 10-27). Following mCMV infection of wild-type BMDM, a significant 243 
temporal activation of Myd88, p50, p65, Trif, Rig-I, Mda5, and Sting was observed (Figure 4A). 244 
The expression profile of Ips-1 was initially suppressed up until 5 hours post infection followed 245 
by an activation, while cGas exhibited an early activation between 1 and 3 hours post infection, 246 
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followed by a rapid drop in expression. Notably, the activation of Trif, which was absent until 247 
3 hours post infection, was followed by a rapid increase in expression peaking at 7 hours. In 248 
Ifnb1-deficient BMDM, mCMV infection resulted in a significant temporal change in 249 
expression of all genes but Trif. While the temporal expression of Myd88, Rig-I, Mda-5, and 250 
Sting was significantly changed over time, the level of expression was much reduced in these 251 
cells, suggesting that IFN-signaling is in part needed for the full induction of these genes. 252 
Notably, while the expression level of cGas was initially much higher in wild-type cells, the 253 
level expression after 5 hours dropped to similar levels as those observed in the Ifnb1-deficient 254 
cells, suggesting that IFN is required for the early activation of this gene. 255 
In poly(I:C) activated wild-type BMDM, significant temporal expression change 256 
was observed for Myd88, p65, Trif, Rig-I, Ips-1, and cGas, consistent with that observed in 257 
mCMV infected cells (Figure 4B). p50, Mda5, and Sting all exhibited an initial increase in 258 
expression between 1-3 hours post treatment, however, unlike Mda5 and Sting that did not 259 
significantly change, the level of p50 expression was reduced between 3-7 hours. The modeled 260 
temporal change in the p50 expression profile was, however, not significant. In Ifnb1-deficient 261 
BMDM, a significant temporal change was observed for all genes with the exception of Trif. 262 
As in infected Ifnb1-deficient BMDM, poly(I:C) treatment resulted in a reduced temporal 263 
expression for Myd88, Rig-I, Mda-5, and Sting. Moreover, Mda5 exhibited a repressed temporal 264 
profile, as compared to its expression in poly(I:C) treated wild-type cells. Notably, Ips-1 and 265 
cGas both exhibited an increased expression over time, with the expression of Ips-1 exceeding 266 
that observed in wild-type cells (Figure 4B).  267 
Collectively, these results suggest intact IFN-signaling is not required for the 268 
expression of p50 and p65 following mCMV infection, but is required for the magnitude in 269 
expression of the upstream components (Myd88, Rig-I, Mda5, and Sting) of these pathways.   270 
 271 
Inhibition of SIRT6 and NAMPT results in increased viral replication. 272 
The observation that Nampt and Sirt6 were coordinately induced in macrophages by immune 273 
stimulation, either by infection or the ensuing interferon response, prompted us to test 274 
whether NAMPT and SIRT6 exhibit antiviral activity. To investigate whether Sirt6 and 275 
Nampt exhibit antiviral properties, mCMV replication was measured after siRNA mediated 276 
knockdown of Sirt6 and after pharmacologic inhibition or siRNA mediated knockdown of 277 
Nampt, with the highly specific non-competitive inhibitor FK866, respectively (48) (Figure 278 
5, Supplementary figure 2). Consistent with the reported antiviral activity of human SIRT6 279 
(49), mediated knockdown of murine Sirt6 resulted, in a siRNA concentration-dependent 280 
manner, in an increased viral replication (Figure 5A). Moreover, siRNA mediated 281 
knockdown and pharmacologic inhibition of murine Nampt also resulted in an increase in 282 
viral replication, respectively (Figure 5B-C). Together, these results indicate that Sirt6 and 283 
Nampt both display antiviral properties, providing druggable targets in bolstering interferon 284 
antiviral immunity linked to sterol metabolism.   285 
 286 
 287 
Discussion 288 
Here we demonstrate upon infection of macrophages the serial activation of Nampt and Sirt6. 289 
The observed rapid kinetics of Nampt induction shows a strict dependency on both type I and 290 
type II IFN signal activation of transcription and, thus, represents an immediate-early class of 291 
Interferon Simulated Genes (ISG). By contrast Sirt6 shows delayed induction kinetics and is 292 
only indirectly activated downstream of viral induced type I IFN signaling.  In agreement, we 293 
find the Nampt promoter region contains multiple consensus Stat1 binding sites whereas these 294 
sites are absent in the Sirt6 promoter region. Notably, pharmacological inhibition of NAMPT 295 
enzymatic activity or knock-down of Nampt or Sirt6 result in increased viral replication 296 
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revealing anti-viral roles for these metabolic regulators in infection. Hence, in an apparent 297 
orchestrated and coordinated manner Nampt enzymatically drives NAD+ production that is a 298 
key rate-limiting co-factor for Sirt6 activation and thereby couples Sirt6 functions to the IFN 299 
antiviral response (Figure 6).  300 
 301 
We further find that temporal expression analysis of key pathway components of 302 
the common TLR signaling pathway, which elicits the activation of NFB and MAPK through 303 
the Myd88 adaptor (43), and the IPS-1 and STING mediated pathways that induce type-I IFN 304 
synthesis, revealed a part dependency on intact type I IFN signaling as loss of Ifnb1 resulted in 305 
a reduced magnitude of expression (Myd88, Rig-I, Mda5, and Sting). The downstream signaling 306 
components of these pathways, p50, p65, Trif, Ips-1, and cGas were on the other hand not 307 
affected in the same way by the loss of Ifnb1. An activated expression profile was, however, 308 
observed for Ips-1 and cGas, suggesting that intact type I IFN signaling might be required for 309 
maintaining a regulated expression of these genes. As for p50 (NFB), an initial increased 310 
expression was observed followed by a gradual (mCMV infection) or rapid (poly(I:C) 311 
treatment) declining expression. A similar expression profile was observed for p65 following 312 
mCMV infection, but not poly(I:C) treatment. Notably, in recent years, SIRT6 has been shown 313 
to inhibit NFB expression (50-52) and NFB target gene activation by interacting with p65 314 
(Figure 6, Summary figure) (51, 53). It is possible that this mode of regulation is reflected in 315 
the observed p50 and p65 expression profiles, nevertheless, further analysis would be required 316 
to confirm this. Whether Sirt6 is regulated by NFB in this system remains to be explored, 317 
however, global profiling of p65 binding sites (by ChIP-seq) in TNF-induced human 318 
osteosarcoma U-2 OS cells (54) and TNF-induced or poly(I:C) stimulated Detroit 562 cells 319 
(55) did not identify SIRT6 as a NFB/p65 target gene. Genome-wide profiling of p65-bound 320 
sites after 3h and 6h of LPS treatment, have on the other hand identified NAMPT as a p65-321 
activated gene (56).  322 
 323 
Together, these findings are consistent with observations, in other systems, that 324 
are supportive of a potential antiviral role for Nampt and Sirt6 (49, 53, 57-60). In a systems-325 
level screen for ISGs with antiviral activity, human NAMPT was identified as one of several 326 
type-I interferon stimulated genes that exhibited, in infected Huh-7 cells, antiviral activity 327 
towards Venezuelan equine encephalitis virus (VEEV), a single-stranded RNA virus (57). 328 
NAMPT has also been reported to exhibit anti-HIV-1 activity, interfering with both early events 329 
of the life cycle (61) and Tat-induced HIV-1 long terminal repeat (LTR) transactivation (58, 330 
59, 62). As for the role of SIRT6 in antiviral immunity this is less known. Koyuncu et al. 331 
reported in a loss-of-function study, that loss of human Sirtuin activity, including SIRT6 332 
activity, in infected fibroblast MRC5 cells resulted, by unknown mechanism, in significant 333 
increases in viral titers (hCMV, HSV-1, Adenovirus, and Influenza A) (49). Moreover, a recent 334 
report by Li et al. show that SIRT6 negatively regulates Dengue virus-induced inflammatory 335 
responses by targeting the DNA binding domain of NFB p65 (53). Notably, unlike our 336 
observations reported here those reported by Koyuncu et al. (49), DENV replication was 337 
reduced in HEK293T cells upon silencing of SIRT6 (53). It is possible that with the diverse 338 
nature of SIRT6 the mechanisms by which it exerts its antiviral function differs depending on 339 
cell type and viral strain, though the mechanism by which Nampt and Sirt6 exert antiviral 340 
effects in these studies is not known. Nevertheless, together with our findings they support the 341 
notion that NAMPT and SIRT6 constitute yet another way by which the macrophage can limit 342 
productive viral infection.  343 
A central mechanism of action worth noting is the reciprocal increase in de novo 344 
Nampt mRNA expression, in IFN stimulated BMDM, is followed by a decrease in Srebf2 345 
transcription. This is consistent with studies demonstrating IFN-antiviral suppression of 346 
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transcription of multiple members of the sterol biosynthesis pathway, in part mediated by a drop 347 
in SREBP2 RNA transcription and protein levels (7). Mechanistic studies of IFN suppression 348 
of macrophage sterol biosynthesis pathway have determined an approximately 40% 349 
contribution by Ch25h and its cognate metabolite 25HC acting at the post-translational level, 350 
and 40% by a post-transcriptional mechanism involving microRNA (miR342-5p). However, 351 
these known mechanisms fail to account for the observed transcriptional effects on Srebf2 352 
levels. In this regard, there is good evidence to show that Sirt6 binds to and regulates Srebf2 353 
via transcription (6, 22). Figure 6 shows a schematic of a proposed mechanism for the anti-viral 354 
activies of Nampt and Sirt6, mediated through epigentic transcriptional suppression of Srebf2, 355 
which encodes the master transcription factor sterol biosynthesis. Figure 6 also highlights the 356 
other proposed molecular pathways for down-regulating the sterol pathway in macrophages 357 
involving the generation of 25-hydroxycholesterol (25HC) and miR342-5p microRNA, both of 358 
which contribute toward modulating the SREBP2 autoregulatory loop in response to interferon-359 
signaling (6, 19).  360 
 It is noteworthy that host-directed targeting of immune modulated cellular 361 
pathways can be used as an innovative therapeutic intervention that also overcomes the antiviral 362 
drug resistance (63). In this regard, we note that SIRT6 inhibitors are under development as 363 
anti-cancer drugs (64-66). Some studies have investigated the efficiency of Ex527 (Selisistat), 364 
a commercially available Sirtuin inhibitor (SigmaAldrich) (67, 68) and another proposed 365 
approach in inhibiting SIRT6 activity is through administration of nicotineamide 366 
(NAM/Vitamin B3), which in addition to being a NAD+ precursor, also acts as an endogenous, 367 
non-competitive Sirtuin inhibitor (69). Thus, there is an opportunity for repurposing these 368 
cancer drugs for potential antiviral therapy. 369 
 370 
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Materials and Methods 388 
Mice 389 
C57BL/6 mice were housed in the specific pathogen-free animal facility at the University of 390 
Edinburgh. Tyk2-/- mice were maintained under specific-pathogen-free conditions at the 391 
Institute of Animal Breeding and Genetics, Department for Biomedical Sciences, University of 392 
Veterinary Medicine Vienna, Vienna, Austria. The generation or source of knockout mouse 393 
strains for Tyk2-/- has been described before (70). All procedures were carried out under project 394 
and personal licenses approved by the Secretary of State for the Home Office, under the United 395 
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Kingdom's 1986 Animals (Scientific Procedures) Act and the Local Ethical Review Committee 396 
at Edinburgh University. 397 
 398 
Cell propagation and culture 399 
NIH-3T3 (ATCC® CRL-1658TM) immortalized cell line of embryonic mouse fibroblasts was 400 
obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA) and grown 401 
in Dulbecco's modified Eagle medium (DMEM) (Lonza, Vervier, Belgium), supplemented with 402 
5% Calf Serum (CS) (Thermo Fisher Scientific, Waltham, MA, U.S.A.), 2mM glutamine 403 
(Lonza) and 50U/ml of penicillin/streptomycin (Lonza). The p53-MEF immortalized cell lines, 404 
of p53-/- embryonic mouse fibroblasts (p53-MEFs , MB355(ATCC® CRT-2818TM)) and Stat1-405 
/-
 p53-/- embryonic mouse fibroblasts (Stat1-/- p53-MEFs), were obtained from American Type 406 
Culture Collection (ATCC) (Manassas, VA, USA). p53-MEFs and Stat1-/- p53-MEFs were 407 
grown in DMEM (Lonza), supplemented with 5% fetal calf serum (FCS) (Thermo Fisher 408 
Scientific), 2mM glutamine (Lonza) and 100U/ml of penicillin/streptomycin (Lonza). BMDM 409 
were isolated and grown in DMEM/F-12 (Ham 1:1) and L-glutaMAX, supplemented with 10% 410 
Fetal Calf Serum (Lonza), 10% L929 and 100U/ml of penicillin/streptomycin. All cells were 411 
grown in accordance to standard procedures. BMDMs were differentiated with CSF-1 derived 412 
from L929 cells for 7 days prior to further treatment. 413 
 414 
Viruses and Reporter Viruses  415 
Wild-type murine cytomegalovirus (MCMV-C3X) has been previously described (71). The 416 
GFP-encoding MCMV (mCMV-GFP) has also been previously described (72). For RNA 417 
expression analysis, infection was done at a multiplicity of index (MOI) of 1 unless else 418 
specified.  419 
 420 
RNAi and Assay for GFP-virus growth 421 
siRNAs and “RISC-free” control siRNA were purchased from Dharmacon® RNAi 422 
Technologies (Thermo Fisher Scientific). miR-342-5p microRNA mimic were kindly gifted by 423 
Integrated DNA Technologies (WOS:000332467100005). The following siRNAs were used: 424 
“RISC-free” siRNA, SiGenomeTM Control (Cat. No. D-001220-01-05); Mouse Sirt6 siRNA 425 
(deconvoluted), ON-TARGETplus siRNA Mouse Sirt6 (Cat. No. J-061392-09, J-061392-10, 426 
J-061392-11, J-061392-12); Mouse Nampt siRNA (deconvoluted), ON-TARGETplus siRNA 427 
Mouse Nampt (Cat. No. J-040272-09, J-040272-10, J-040272-11, J-040272-12); M54 siRNA, 428 
custom made order from Dharmacon® (5’-3’ sense strand sequence is 429 
AGAAAGACGACCTGAGCTA). Mimics and siRNA were transfected into cells (NIH-3T3), 430 
in a 96 well plate, using DharmaFECT1 (Thermo Fisher Scientific) using the reverse-431 
transfection method and in accordance to the manufacturer’s recommendations. M54 siRNA 432 
and miR-342-5p microRNA mimic were transfected at a final concentration of 25nM and Sirt6 433 
siRNA was transfected at a final concentration of 6.25, 12.5, and 25 nM/well. For the analysis 434 
of miR-342-5p inhibitor effects on virus replication, medium containing 3% delipidized serum 435 
(Bovine Serum, Lipid Depleted (Part number: S181L), VWR, UK) was used. After 48h, 436 
MCMV-GFP (MOI 0.025) was used for infection. The viral growth (fluorescence in each well) 437 
was measured using a POLARstar OPTIMA plate reader (BMG Labtech, Aylesbury, UK) 438 
according to manufacturer’s recommendations. The RNAi and viral growth assay were set up 439 
as two independent experiments with 3 biological replicates per experiment (n=6). Virus 440 
replication slopes over the linear phase were calculated, from 68 hours to the end of the time 441 
course, and then normalized to control transfected wells. Statistical significance was determined 442 
using One-way ANOVA with a Dunnett’s multiple comparisons test. P-values of <0.05, <0.01 443 
and <0.001 were considered significant. 444 
 445 
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In-silico promoter analysis. 446 
In silico promoter analysis of the NAMPT and SIRT6 promoter regions was done using 447 
PROMO, a virtual laboratory for identification of putative transcriptional binding sites (33, 34). 448 
The promoter regions consisting of the 1kb upstream regions of murine and human NAMPT 449 
and SIRT6 were retrieved from the Mouse Genome Informatics (MGI) Web Site (73-75) and 450 
The National Center for Biotechnology Information (NCBI) (76) resource, and imported into 451 
the online PROMO analysis tool. Species specific (Mus musculus or Homo sapiens) 452 
transcription factors and transcription factor sites were chosen. For murine Nampt and Sirt6, 453 
306 and 270 putative transcription factor binding sites within a dissimilarity margin less or 454 
equal than 15% were identified in the promoter regions, respectively. For human NAMPT and 455 
SIRT6, 444 and 436 putative transcription factor binding sites within a dissimilarity margin less 456 
or equal than 15% were identified in the promoter regions, respectively. All identified putative 457 
binding sites can be found in Supplementary Tables 1-4. From these, the most probably 458 
immune-regulatory and core transcription factor binding sites were identified via manual 459 
procurement by comparing putative binding site to publicly available/published consensus 460 
binding sequences for each transcription factor.  461 
 462 
IFN- treatment of p53-MEFs and isolation 463 
Wild-type and Stat1-/- p53-MEFs were plated, in a 24-well plate, at a cell density of 3x105 464 
cells/well and grown in DMEM (Lonza), supplemented with 5% fetal calf serum (FCS) 465 
(Thermo Fisher Scientific), 2mM glutamine (Lonza) and 100U/ml of penicillin/streptomycin 466 
(Lonza), for 24 hours prior to treatment with murine recombinant IFN gamma (IFNPerbio 467 
Science. The IFNwas diluted in complete medium and added to cells at a final concentration 468 
of 10U/ml. Cells were harvested at 1, 2, 4, 8, and 16 hours post treatment for quantitative real-469 
time PCR analysis using 350 µl Qiagen RTL Plus buffer (Qiagen RNeasy Plus kit) as per 470 
manufacturer’s recommendations. 471 
 472 
BMDM IFN- treatment, RNA labelling and isolation 473 
Incorporation of 4-thiouridine (Sigma-Aldrich, St. Louis, MI, U.S.A) into newly-transcribed 474 
RNA was undertaken as described by Dölken et al. (77) and Robertson et al. (6). In brief, at 475 
time zero medium was aspirated from all plates and 15ml of pre-warmed medium containing 476 
IFN-γ (final concentration of 10U/ml) or normal medium was added to the cultures. RNA 477 
labelling in BMDM during the first 30 minutes of the time course was undertaken by addition 478 
of 200µM 4-Thiouridine to the medium of appropriate plates at this time. After 30 minutes, to 479 
end the RNA labelling period, terminate transcription and lyse the cells, medium was aspirated 480 
from the labelled BMDM and replaced with 4mls of RLT lysis buffer (Qiagen, Hilden, DE). In 481 
parallel, 10ml of medium from the next BMDM cultures to be labelled was added to an 482 
appropriate volume of 4-thiouridine, mixed and immediately added back to the plate. BMDM 483 
cultures were then returned to the incubator. The above cycle of 4-thiouridine addition to 484 
BMDM cultures and transcriptional termination was repeated at 30-minute intervals until the 485 
end of the time course. Total RNA was isolated using RNeasy Midi kit (Qiagen) according to 486 
manufacturer’s instructions, quantitated using a Nanodrop (Thermo Scientific) and integrity 487 
was confirmed using an Agilent Bioanalyser (Agilent UK). Newly transcribed RNA (ntRNA) 488 
was then isolated as described in Dölken et al. (77) and Robertson et al. (6) and again 489 
quantitated using a Nanodrop, followed by qRT-PCR. 490 
 491 
Quantitative real-time PCR (qRT-PCR) Analyses of individual genes 492 
Cells were harvested in 350 µl Qiagen RTL Plus buffer (Qiagen RNeasy Plus kit) as per 493 
manufacturer’s recommendations. Total RNA was extracted from cells with RNeasy Plus kit 494 
(Qiagen) according to the manufacturer’s instructions and quantitated using a Nanodrop 495 
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(Thermo Scientific). All experiments were performed on three biological replicates/samples 496 
(n=3) and expression analysis were performed with three technical replicates/sample (n=3), 497 
unless else specified. Quantitative gene-expression analyses were performed using Taqman® 498 
Primer probe sets (Applied Biosystems, Warrington, UK). Mouse Assay ID: NAMPT: 499 
Mm00451938_m1, SIRT6: Mm01149042_m1, SREBF2: Hs01081784_m1, Actin Beta (ACTB 500 
FAM): Mm02619580_g1. Quantitative real-time PCR was performed either as one-step 501 
reactions (qRT-PCR) or two-step reactions (RT-qPCR) with an initial separate cDNA synthesis 502 
step. qRT-PCR and RT-qPCR were performed in a Stratagene MX3000P machine (Stratagene 503 
California, San Diego, CA, U.S.A). For qRT-PCR, each sample reaction was performed in 10µl 504 
volumes using 96-well Non-Skirted, White PCR Plates (ABgene, UK) and MicroAmp Optical 505 
Caps (Applied Biosystems, UK). For one reaction, 50ng of diluted total RNA samples was 506 
added to 2.5µl of 4x qScript One-Step Fast qRT-PCR (Low ROX) master-mix, 0.5µl qScript 507 
One-step Reverse Transcriptase (Cat. No. 95081, Quanta Biosciences, USA), 0.5µl of Taqman 508 
primer/probe set (Applied Biosystems), and RNase-free H2O to a total volume of 10 µl. cDNA 509 
synthesis by reverse-transcription was performed at 50°C for 5 minutes, followed by initial 510 
denaturation at 95°C for 30 seconds, and  40 cycles of combined denaturation at 95°C for 511 
3 seconds followed by annealing/primer extension (detection) at 60°C for 30 seconds. For two-512 
step analysis, 500ng of isolated total RNA was used for cDNA synthesis with random hexamers 513 
using SuperScript® III Reverse Transcriptase (Thermo Fisher Scientific) following the 514 
manufacturer’s instructions. Following cDNA synthesis, qPCR was performed in 10µl 515 
volumes. For one reaction, 50ng cDNA (equivalent to 50ng total RNA) was added to 5 µl of 2x 516 
PerfeCta® qPCR ToughMixTM (Low ROX) master-mix, 0.5µl of Taqman primer/probe set 517 
(Applied Biosystems), and RNase-free H2O to a total volume of 10µl. Expression of target 518 
genes was normalized to ActB. The normalized data were used to quantify the relative levels 519 
of a given mRNA according to comparative cycle threshold (2−ΔΔCT) analysis (78, 79).  520 
Statistical significance in Nampt and Sirt6 expression was calculated using One-way ANOVA 521 
with a Tukey’s or Sidak’s multiple comparisons test (between wild-type and Stat1-/- p53-522 
MEFs). Statistical significance for knock-down efficiency of Nampt and Sirt6 was determined 523 
using One-way ANOVA with a Dunnett’s multiple comparisons test. P-values of <0.05, <0.01 524 
and <0.001 were considered significant.  525 
 526 
Pharmacological inhibition of NAMPT with FK866 and Viral Plaque Assay. 527 
Pharmacological inhibition of NAMPT was done using FK866 (48) at a final concentration of 528 
10mM. Briefly, NIH-3T3 cells were seeded in a 48 well plate at a cell density of 1x105 529 
cells/well and infected with MCMV-GFP (MOI 0.1) the following day. After the adsorption 530 
period, the infection media was replaced with media with FK866 (10 nM) or without (control). 531 
Cells were assessed for viral growth (GFP signal) over a 4-day period at which point the cells 532 
were harvested and frozen down at -80°C. The effect of FK866 treatment on viral growth was 533 
quantified by plaque assay on p53-/- MEF monolayers in 48-well plates using standard 534 
methodology. Statistical significance was determined using unpaired T test with Welch’s 535 
correction. P-values of <0.05, <0.01 and <0.001 were considered significant.  536 
 537 
 538 
Time-Course Microarray analysis  539 
Temporal expression analysis for Nampt, Sirt6, and Stat1 in wild-type and IFNB-/- BMDM are 540 
based off previously generated microarray data published by Blanc et al. (21). Briefly, wild-541 
type, and IFNB-/- BMDM were either infected with MCMV (MOI 1) or treated with or poly(I:C) 542 
(25g/ml) or IFN (10U/ml). Cells infected with MCMV or treated with poly(I:C) were 543 
harvested at 0, 2, 4, 6, 8, 10, and 24 hours post-treatment for RNA isolation and microarray 544 
analysis (Affymetrix Mouse Gene 1.0ST microarray). Cells treated with IFN were harvested 545 
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every 60 minutes for a total of 12 hours post-treatment for RNA isolation and microarray 546 
analysis (Affymetrix Mouse Gene 1.0ST microarray). In brief, the arrays were normalized using 547 
the gcRMA algorithm (80) and imported into Partek Genomics Suite (Partek, U.S.A) for 548 
downstream analysis (21). Temporal expression data for Nampt in MCMV-infected wild-type 549 
and Tyk2-/- BMDM was generated using microarray. BMDM isolated from wild-type and Tyk2-550 
/-
 mice were cultivated for 7 days. Following 7 days, cells were infected with MCMV (MOI 1) 551 
and harvested 1-1.5 and 6-6.5 hours post infection followed by RNA isolation (RNeasy Midi 552 
kit, Qiagen) and microarray analysis (Affymetrix Mouse Gene 1.0ST microarray). Time course 553 
microarray analysis data are compliant with the National Centre for Biotechnology Information 554 
Gene Expression Omnibus (GEO) (81) under SuperSeries accession number GSE42505 555 
(SubSeries numbers GSE42503, GSE42504) (GEO, http://www.ncbi.nlm.nih.gov/geo/). 556 
Macrophage microarray data will be deposited in Gene Expression Omnibus and will be 557 
accessible through GEO. 558 
 559 
 560 
Statistical analysis of time-course microarray data 561 
Prior to statistical analysis, gene expression data (0-24 hours post mCMV infection or poly(I:C) 562 
treatment) was smoothened by taking the mean of every consecutive pair of points, i.e. mean 563 
of score at 0 and 2 hours defined the score at 1 (hour) and mean of 2 and 4 hours defined the 564 
score at 3 (hours), 4 and 6 hours defined the score at 5 (hours), 6 and 8 hours defining the score 565 
at 7 (hours), and 8 and 10 hours defining the score at 9 (hours). Smoothing was not done beyond 566 
10 hours as the gap to the next point at 24 hours was too large and, thus, excluded from analysis. 567 
This type of smoothing preserves the patterns in the data while removing some of the fine scale 568 
rapid changes. To investigate whether the gene expression changed over time, the mean 569 
smoothed data (or non-smoothened for the 12h-dataset) for each gene expression was compared 570 
to a straight horizontal line. This was achieved by fitting the data to an appropriate polynomial 571 
in time t, i.e. either a linear model (� = ߙ + ߚ�ሻ, or a quadratic model (� = ߙ + ߚ� + ߛ�ଶሻ or 572 
a cubic model ሺ� = ߙ + ߚ� + ߛ�ଶ + ߜ�ଷሻ. If the coefficients other than the intercept (ߙ) were 573 
significant then the model and hence the gene expression, must vary with time.  Which model 574 
was chosen depended on the model fit as given by the R2 value – the higher the better. The great 575 
majority of the fits were very strong - R2 > 0.9. To determine then if the model deviated 576 
significantly for the horizontal, the significance attached to each of the coefficients (ߚ, ߛ , ߜሻ of 577 
the time variables was investigated. If anyone of these was significant at the p < 0.05 level or 578 
if any two were significant at the 0.05 < p < 0.1 level then we considered the model and the 579 
gene expression to vary significantly with time. Refer to Supplementary tables 5-29 for the 580 
results of the statistical analysis. 581 
 582 
 583 
Figure legends 584 
Figure 1. Putative transcription factor binding sites within the promoter regions of 585 
murine Nampt and Sirt6 and human NAMPT and SIRT6. 586 
In silico analysis using PROMO of the murine Nampt and Sirt6 and human NAMPT and SIRT6 587 
promoter regions revealed putative binding sites for an array of different immune-regulatory 588 
transcription factors (TF) (Supplementary tables 1-4). The cut off for  dissimilarity to the 589 
consensus TF binding-sequence was set to 15 % (* marks binding sites with low percentage, 0-590 
4%, dissimilarity) and the identified string sequences were compared to the consensus binding 591 
site sequences for each transcription factor. Figure is not to scale.  592 
 593 
Figure 2. Expression of Nampt and Sirt6 is upregulated by MCMV infection. 594 
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(A) Quantification of relative Nampt and Sirt6 mRNA expression in NIH-3T3 cells, at 6 and 595 
10 hours, using RT-qPCR following mCMV infection with mock-infected cells serving as 596 
controls (n=3). (B) Quantification of relative Nampt and Sirt6 mRNA expression in p53-MEF 597 
cells, at 3 and 6 hours, using RT-qPCR following mCMV infection (n=3). ANOVA with Tukey 598 
post test was used to assess statistical signficance. (C) Normalized temporal Nampt and Sirt6 599 
expression (antilog) in mCMV infected bone marrow derived macrophages (BMDM). The 600 
expression was measured over the first 24 hours of infection using microarray and compared to 601 
timepoint 0. The expression levels between 0-10 hours were smoothened and fitted to a linear 602 
(+), quadatic (#), or cubic (*) polynomal on time and the statistical significance (p-values) was 603 
assessed. +/#/* p < 0.05, ++/##/** p < 0.01, and +++/###/*** p < 0.001 were considered to be 604 
significant (ns, not significant).. Bars represent standard error of the mean (SEM). * p < 0.05, 605 
** p < 0.01, and *** p < 0.001 were considered to be significant (ns, not significant). 606 
 607 
Figure 3. Expression of Nampt is induced by both type-I and type-II IFN, while respone 608 
of Sirt6 is restricted to type-I IFN response. (A) Quantification of Nampt mRNA expression, 609 
using microarray, in wild-type (wt) and Tyk2-/- BMDM following mock- (control) and mCMV-610 
infection.  (B) Normalized temporal expression (antilog) of Nampt and Sirt6 in mCMV infected 611 
wild-type and Ifnb-/- BMDM. The expression was measured over the first 24 hours of infection 612 
using microarray and compared to timepoint 0. The expression levels between timepoints 0-10 613 
hours post streatment were smoothened and fitted to a linear (+), quadatic (#), or cubic (*) 614 
polynomal on time to assess significance (p-values). +/#/* p < 0.05, ++/##/** p < 0.01, and 615 
+++/###/*** p < 0.001 were considered to be significant (ns, not significant). (C) Normalized 616 
temporal expression (antilog) of Nampt and Sirt6 in poly(I:C) treated wild-type and Ifnb-/- 617 
BMDM. The expression was measured over the first 24 hours using microarray and compared 618 
to timepoint 0. The expression levels between timepoints 0-10 hours post streatment were 619 
smoothened and fitted to a linear (+), quadatic (#), or cubic (*) polynomal on time to assess 620 
significance (p-values). +/#/* p < 0.05, ++/##/** p < 0.01, and +++/###/*** p < 0.001 were considered 621 
to be significant (ns, not significant). (D) Quantification of de novo synthesis of Nampt, Sirt6, 622 
and Srebf2 mRNA in IFN-stimulated BMDMs using qRT-PCR. Expression was measured 623 
every 30 min for a total of 8 hours. (E) Quantification of relative Nampt mRNA expression in 624 
wild-type and Stat1-/- p53-MEF cells, at 1, 2, 4, 8, and 16 hours, using RT-qPCR following 625 
IFN stimulation (n=3). Expression is relative to wild-type untreated (0h) cells, set as 1 (not 626 
shown). One-way ANOVA with a Tukey’s post test was used to assess statistical signficance 627 
to untreated controls. One-way ANOVA with a Sidak’s multiple comparisons test was used to 628 
assess statistical signficance between wild-type and Stat1-/- mutants. Bars represent standard 629 
error of the mean (SEM). Statisical significance between groups (wild-type and Stat1-/-) were 630 
depicted with *. Statistical significance in relation to untreated controls (wild-type and Stat1-/-, 631 
respectively) were depicted with #. * and # p < 0.05, ** and ## p < 0.01, *** and ### p < 0.001 632 
were considered to be significant. (F) Quantification of relative Sirt6 mRNA expression in wild-633 
type and Stat1-/- p53-MEF cells, at 1, 2, 4, 8, and 16 hours, using RT-qPCR following IFN 634 
stimulation (n=3). Expression is relative to wild-type untreated (0h) cells, set as 1 (not shown). 635 
One-way ANOVA with a Tukey’s post test was used to assess statistical signficance to 636 
untreated controls. One-way ANOVA with a Sidak’s multiple comparisons test was used to 637 
assess statistical signficance between wild-type and Stat1-/- mutants. Bars represent standard 638 
error of the mean (SEM). Statisical significance between groups (wild-type and Stat1-/-) were 639 
depicted with *. Statistical significance in relation to untreated controls (wild-type and Stat1-/-, 640 
respectively) were depicted with #. * and # p < 0.05, ** and ## p < 0.01, *** and ### p < 0.001 641 
were considered to be significant.  642 
 643 
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Figure 4. Expression of upstream, but not downstream, TLR signaling pathway 644 
components is dependent on IFN/type-I IFN signaling. 645 
(A) Normalized temporal expression (antilog) of Myd88, p50 (Nfkb1), p65 (Rela), Trif 646 
(Ticam1), Rig-I (Ddx58), Mda-5 (Ifih1), Ips-1 (Mavs), Sting (Tmem173), and cGas (Mb21d1) 647 
in mCMV infected wild-type and Ifnb-/- BMDM. The expression was measured over the first 648 
24 hours of infection using microarray and compared to timepoint 0. The expression levels 649 
between timepoints 0-10 hours post streatment were smoothened and fitted to a linear (+), 650 
quadatic (#), or cubic (*) polynomal on time to assess significance (p-values). +/#/* p < 0.05, 651 
++/##/** p < 0.01, and +++/###/*** p < 0.001 were considered to be significant (ns, not significant). 652 
(B) Normalized temporal expression (antilog) of Myd88, p50 (Nfkb1), p65 (Rela), Trif 653 
(Ticam1), Rig-I (Ddx58), Mda-5 (Ifih1), Ips-1 (Mavs), Sting (Tmem173), and cGas (Mb21d1) 654 
in poly(I:C) treated wild-type and Ifnb-/- BMDM. The expression was measured, as in A, over 655 
the first 24 hours using microarray and compared to timepoint 0. The expression levels between 656 
timepoints 0-10 hours post streatment were smoothened and fitted to a linear (+), quadatic (#), 657 
or cubic (*) polynomal on time to assess significance (p-values). +/#/* p < 0.05, ++/##/** p < 0.01, 658 
and +++/###/*** p < 0.001 were considered to be significant (ns, not significant). 659 
 660 
Figure 5. Inhibition of NAMPT and SIRT6 activity increases viral loads in MCMV 661 
infected cells. (A) Normalized replication slope of mCMV-GFP in Sirt6 siRNA-treated NIH-662 
3T3. “RISC-free”  siRNA served as negative control and miR342-5p siRNA served as positive 663 
control. (B) Normalized replication slope of mCMV-GFP in Nampt siRNA-treated NIH-3T3, 664 
with M54 serving as positive control. Bars represent standard error of the mean (SEM). 665 
Statistical significance was determined using One-way ANOVA with a Dunnett’s multiple 666 
comparisons test. * p < 0.05, ** p < 0.01, and *** p < 0.001 were considered to be significant 667 
(ns, not significant). (C) mCMV-GFP replication (titer) in NIH-3T3 after pharmacological 668 
inhibition of NAMPT with FK866 (10nM final concentration). mCMV-GFP was propagated in 669 
NIH-3T3 fibroblasts and quantified by plaque assay on p53-MEF monolayers in 48-well plates. 670 
Statistical significance was determined using unpaired T test with Welch’s correction. * p < 671 
0.05 wasconsidered to be significant. 672 
 673 
Figure 6.  Summary figure. 674 
 675 
 676 
Supplementary figure legends: 677 
 678 
Supplementary figure 1. Nampt expression in macrophages is Jak/Stat-dependent and 679 
induced by IFN stimulation. 680 
Normalized temporal Nampt expression in IFN-treated BMDM. The expression was measured 681 
hourly over the first 12 hours of treatment using microarray, and the expression levels were 682 
fitted to a cubic polynomal on time and assessed for statitical significance (temporal change 683 
over 12 hours). ### p < 0.001 were considered to be significant. 684 
 685 
Supplementary figure 2. Knock-down efficiency of Nampt and Sirt6 in NIH-3T3 cells. 686 
(A) Quantification of relative Nampt mRNA expression in NIH-3T3 cells following using qRT-687 
PCR following siRNA treatment (6.25nM, 12.5nM, and 25nM siRNA) (n=3). (B) 688 
Quantification of relative Sirt6 mRNA expression in NIH-3T3 cells following using qRT-PCR 689 
following siRNA treatment (6.25nM, 12.5nM, and 25nM siRNA) (n=3). One-way ANOVA 690 
with a Dunnett’s multiple comparisons test was used to determine statistical significance.  Bars 691 
represent standard error of the mean (SEM). * p < 0.05, ** p < 0.01, and *** p < 0.001 were 692 
considered to be significant (ns, not significant). 693 
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